---
title: "石藥 SYH 9089 注射液獲批中國臨牀"
description: "石藥公佈，集團開發的羅哌卡因長效注射液 (SYH 9089 注射液) 已獲得國家藥品監督管理局批准，可在中國開展臨牀試驗。集團指，透過其長效藥物遞送技術平台，該產品可將單次給藥鎮痛持續時間延長至一週，有望成為中國首款鎮痛持續時間達到一週的超長效鎮痛產品。"
type: "news"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/276035823.md"
published_at: "2026-02-16T06:09:51.000Z"
---

# 石藥 SYH 9089 注射液獲批中國臨牀

> 石藥公佈，集團開發的羅哌卡因長效注射液 (SYH 9089 注射液) 已獲得國家藥品監督管理局批准，可在中國開展臨牀試驗。集團指，透過其長效藥物遞送技術平台，該產品可將單次給藥鎮痛持續時間延長至一週，有望成為中國首款鎮痛持續時間達到一週的超長效鎮痛產品。

石藥 (01093.HK) 公佈，集團開發的羅哌卡因長效注射液 (SYH 9089 注射液) 已獲得國家藥品監督管理局批准，可在中國開展臨牀試驗。

集團指，透過其長效藥物遞送技術平台，該產品可將單次給藥鎮痛持續時間延長至一週，有望成為中國首款鎮痛持續時間達到一週的超長效鎮痛產品。

### Related Stocks

- [01093.HK - 石藥集團](https://longbridge.com/zh-HK/quote/01093.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Nomura Adjusts CSPC Pharmaceutical Group's Price Target to HK$12.04 From HK$9.11, Keeps at Buy | Nomura Adjusts CSPC Pharmaceutical Group's Price Target to HK$12.04 From HK$9.11, Keeps at Buy | [Link](https://longbridge.com/zh-HK/news/276056763.md) |
| CSPC Pharmaceutical Receives Regulatory Nods to Begin Drug Trials | CSPC Pharmaceutical Receives Regulatory Nods to Begin Drug Trials | [Link](https://longbridge.com/zh-HK/news/276035104.md) |
| Hangzhou Jiuyuan Gene Engineering IND Application for JY54 Injection Accepted by CDE | Hangzhou Jiuyuan Gene Engineering Co. Ltd. has announced that its IND application for JY54 Injection has been accepted b | [Link](https://longbridge.com/zh-HK/news/275289286.md) |
| CSPC Pharmaceutical says ropivacaine long-acting injection approved for clinical trials in China | CSPC Pharmaceutical says ropivacaine long-acting injection approved for clinical trials in China | [Link](https://longbridge.com/zh-HK/news/276051793.md) |
| CSPC Pharma Gets China Nod for Multiple Drug Trials | CSPC Pharma Gets China Nod for Multiple Drug Trials | [Link](https://longbridge.com/zh-HK/news/270994613.md) |

---

> **免責聲明**：本文內容僅供參考，不構成任何投資建議。